“Pushpa 2: The Rule Day 16 Box Office: Allu Arjun’s Blockbuster Earns ₹25 Crore on Third Saturday”

Date:

Share post:

Pushpa 2: The Rule Box Office Day 16: Allu Arjun’s Action Drama Continues to Soar, Earns ₹25 Crore on Third Saturday

Allu Arjun’s blockbuster Pushpa 2: The Rule continues its phenomenal run at the box office, minting ₹25 crore on its third Saturday. The film’s total earnings have now skyrocketed to an astonishing ₹1029.9 crore, making it a cinematic juggernaut.

According to a Sacnilk report, Saturday’s earnings included ₹4.35 crore from Telugu screenings, ₹20 crore from Hindi shows, ₹55 lakhs from Tamil screenings, ₹8 lakh from Kannada audiences, and ₹2 lakh from the Malayalam market. The action-drama recorded an impressive Telugu occupancy rate of 42.21%, reflecting its enduring appeal across the nation.

A Record-Breaking Milestone

Directed by Sukumar, Pushpa 2: The Rule is the sequel to the 2021 hit Pushpa: The Rise. The film’s Hindi version has also been a massive success. Bollywood trade analyst Taran Adarsh shared the third Friday collection of the Hindi version, stating, “Pushpa 2 continues to dominate the box office, despite fresh competition. Rakes in double-digit collections, showcasing remarkable staying power. Solid growth is expected on Saturday and Sunday. Pushpa2 [Week 3] Fri 12.50 cr. Total: ₹645 cr.”

Allu Arjun Reacts to the Success

At a “Thank You” press meet in Delhi, Allu Arjun expressed his gratitude and excitement about the film’s record-breaking success.

“It feels incredible to be sitting on top of a record-breaking hit, and I won’t deny that numbers matter to me. Of course, they do, and I’ll be in this trance for a couple of months because being part of a ₹1000 crore film is no joke,” the actor said.

He added, “The numbers are temporary, but the love I hold very close to my heart. I always say that records are made to be broken. Maybe for the next 2-3 months, I will enjoy all these records, but hopefully, by the summer, I would want all these records to be broken by the next film.”

Vision for Indian Cinema

Allu Arjun also shared his vision for Indian cinema’s growth, saying, “It doesn’t have to be a Telugu film; it can be Tamil, Kannada, or Hindi. It doesn’t matter, but I want these records to be broken because that is the progression. India is going up.”

Pushpa 2: The Rule has undoubtedly set a benchmark for Indian cinema, reaffirming Allu Arjun’s position as one of the most bankable stars in the industry and showcasing the pan-India appeal of Telugu cinema.

Sources By Agencies

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Related articles

“Azaad Box Office Collection Day 1: Rasha Thadani and Aaman Devgan’s Debut Film Earns ₹1.5 Crore on Opening Day”

Bollywood debutants Rasha Thadani and Aaman Devgan make a mark in ‘Azaad,’ which opened with a modest ₹1.5 crore at the box office.

“Azaad Review: A Disastrous Debut with a Flawed Plot and Performances”

The film Azaad, directed by Abhishek Kapoor, is an unfortunate misstep that undermines the careers of two star-relatives — Raveena Tandon's daughter Rasha Thadani and Ajay Devgn's nephew Aaman Devgan. The movie, which aims to combine elements of classic films like Romeo & Juliet and Lagaan, fails to deliver on almost every front, from its weak and erratic screenplay to the lack of proper character development.

“Dipika Chikhlia Honors Late Co-Star Aman Jaiswal with Heartfelt Tribute”

Television actor Aman Jaiswal tragically lost his life on Friday in a road accident in Mumbai. The 23-year-old actor was riding his motorbike on the Jogeshwari-Vikhroli Link Road when a truck collided with him. Jaiswal, who was rushed to Cama Hospital, succumbed to his injuries

Exploring Nutraceuticalsthe Growing Markets of Nutraceuticals and Skincare in India By Pulkit Goyal

In the ever-evolving landscape of healthcare and wellness, AvtixPharmaceuticals emerges as a trailblazer, redefining innovation and quality across multiple sectors. With a steadfast commitment to improving lives, Avtix Pharmaceuticals specializes in four key areas: Pharmaceuticals, Nutraceuticals, Skincare, and Cosmetics.